Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B.

J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14.

2.

EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY.

Nat Neurosci. 2015 Sep;18(9):1236-46. doi: 10.1038/nn.4088. Epub 2015 Aug 10.

3.

WITHDRAWN: Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells.

Ge F, Wang DD, Li L, Lin PP, Shuman MA.

Am J Pathol. 2014 Oct 17. pii: S0002-9440(14)00536-7. doi: 10.1016/j.ajpath.2014.08.023. Epub 2014 Oct 17. Retraction in: Am J Pathol. 2015 Feb;185(2):597.

PMID:
25451150
4.

Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL.

Clin Cancer Res. 2014 Feb 15;20(4):1029-41. doi: 10.1158/1078-0432.CCR-13-0474. Epub 2013 Nov 4.

5.

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE.

Blood. 2013 Jan 31;121(5):745-51. doi: 10.1182/blood-2012-07-440974. Epub 2012 Nov 29.

6.

Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics.

Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman MA, Jan YN, Jan LY.

Genes Dev. 2012 Aug 15;26(16):1780-96. doi: 10.1101/gad.193789.112. Epub 2012 Aug 1.

7.

Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.

Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL.

Clin Cancer Res. 2012 Feb 15;18(4):1146-55. doi: 10.1158/1078-0432.CCR-11-0625. Epub 2012 Jan 6.

8.

Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors.

Sun C, Su KH, Valentine J, Rosa-Bauza YT, Ellman JA, Elboudwarej O, Mukherjee B, Craik CS, Shuman MA, Chen FF, Zhang X.

ACS Nano. 2010 Feb 23;4(2):978-84. doi: 10.1021/nn900757p.

9.

Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL.

Clin Cancer Res. 2009 Mar 15;15(6):1989-97. doi: 10.1158/1078-0432.CCR-08-2054. Epub 2009 Mar 10.

10.

Differential gene expression in central nervous system lymphoma.

Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA.

Blood. 2009 Jan 1;113(1):266-7; author reply 267-8. doi: 10.1182/blood-2008-04-152835. No abstract available.

11.

Protein biomarker identification in the CSF of patients with CNS lymphoma.

Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL.

J Clin Oncol. 2008 Jan 1;26(1):96-105. Epub 2007 Dec 3.

12.

Quinine/quinidine-induced thrombocytopenia: a great imitator.

Reddy JC, Shuman MA, Aster RH.

Arch Intern Med. 2004 Jan 26;164(2):218-20. No abstract available.

PMID:
14744847
13.

Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model.

Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA.

Prostate Cancer Prostatic Dis. 2003;6(4):272-80.

PMID:
14663466
14.

Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.

Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman MA, Craik CS.

Biol Chem. 2003 Feb;384(2):257-66.

PMID:
12675519
15.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.

Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA.

Blood. 2003 Jan 15;101(2):466-8. Epub 2002 Sep 5.

16.

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.

Cancer Res. 2001 Mar 15;61(6):2533-6.

17.

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.

Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA.

Neoplasia. 2000 Jul-Aug;2(4):306-14.

19.

Interferon-induced thrombocytopenia: is it time for thrombopoietin.

Martin TG, Shuman MA.

Hepatology. 1998 Nov;28(5):1430-2. No abstract available.

PMID:
9794932
20.

Death-defying yeast identify novel apoptosis genes.

Shaham S, Shuman MA, Herskowitz I.

Cell. 1998 Feb 20;92(4):425-7. Review. No abstract available.

Supplemental Content

Loading ...
Support Center